Munus Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 23-05-2024
- Paid Up Capital ₹ 1.00 M
as on 23-05-2024
- Company Age 8 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
About Munus Pharmaceuticals
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Viswanath Gopal, Sivasankara Nandakumar, Madhu Manohar, and Six other members serve as directors at the Company.
- CIN/LLPIN
U24304KL2016PTC047341
- Company No.
047341
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Nov 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Thrissur, Kerala, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Munus Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madhu Manohar  | Managing Director | 23-Nov-2016 | Current |
Board Members(8)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Pallipuram Sahasranaman | Nominee Director | 29-Sep-2018 | Current |
| Viswanath Gopal | Director | 09-Jun-2018 | Current |
| Sivasankara Nandakumar | Director | 23-Nov-2016 | Current |
| Sajimon Abraham | Nominee Director | 27-Nov-2017 | Current |
| Sukumar Amrutha | Nominee Director | 25-Nov-2020 | Current |
| Panadan Shaju | Nominee Director | 23-Nov-2016 | Current |
Financial Performance of Munus Pharmaceuticals.
Munus Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Munus Pharmaceuticals?
In 2017, Munus Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Elma Pharmaceuticals Private LimitedActive 20 years 2 monthsSajimon Abraham, Sukumar Amrutha and 3 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Munus Pharmaceuticals?
Munus Pharmaceuticals has a workforce of 14 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Munus Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Munus Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
